PAIRimmune Brochure
PAIRimmune is more than a preclinical contract research organisation (CRO) for early proof-of-concept studies with adapted immune readouts.
PAIRimmune is a contract research organisation (CRO) providing pre-clinical research services, specialising in immunology assessment.
PAIRimmune is a contract research organisation (CRO) that specialises in pre-clinical studies for immunology assessment.
With more than 20 years’ experience in a wide range of in-vivo and in-vitro studies, the company determines the most suitable scientific approach from its in-house animal models. It offers custom services to suit all client needs, utilising biopharmaceutical and CRO abilities with state-of-the-art methods to help biological products gain approval.
PAIRimmune tests vaccines, adjuvants, and immunotherapy candidates in small and large animal models. The company uses models in species such as mouse, rat, hamster, guinea pig, ferret, and pig to help test efficacy against various pathogens and pathologies. These are administered via routes such as intravenously, intramuscularly, intradermally, orally, sublingually, or intraperitoneally.
Analysis technologies incorporated by PAIRimmune include enzyme-linked immunosorbent assay (ELISA), enzyme-Linked ImmunoSpot (ELISPOT), flow cytometry, immunohistochemistry, immunofluorescence (IF), neutralisation assays, and anti-body derived cellular cytotoxicity.
PAIRimmune uses different animal models to evaluate vaccine candidates. A standard package of procedures is available, including clinical signs, body weight, and temperature, as well as arterial oxygenation and activity scoring.
The company also performs viral loads on pathogen-specific procedures and helps with biosafety level 2 bacteria, virus, or other microorganism.
PAIRimmune provides expertise in FACS related to immune responses.
It performs phenotyping (identification and counting of specific cell populations), ICS (identification of cytokines and transcription factors), proliferation (quantification of cellular proliferation levels), and survival (identification of apoptotic / necrotic cells) to quantify viability.
The company offers consulting for antibody cocktails, and troubleshoots gating strategies.
PAIRimmune also acquires up to ten colours for samples on-demand.
PAIRimmune offers packages for immunohistochemistry (IHC) and immunofluorescence (IF) procedures, including organ collection, embedding, preparation of slides, staining, acquisition of images, and analysis.
The company works with optimal cutting temperature (OCT) or formaline fixed paraffin embedded (FFPE) tissues for immunochemistry (IC), IF, and counterstaining to help develop protocols, select antibodies, and optimise troubleshooting.
Using lyceraldehyde 3-phosphate dehydrogenase (GAPDH) measurement technology or flow cytometry approach, PAIRimmune offers in-vitro cytotoxicity measurements for cancer and antiviral immunotherapy testing. The company distinguishes the different populations that could perform this cytotoxicity, such as T lymphocyte (T cells) or natural killer (NK) cells, and measure antibody-derived cellular cytotoxicity.
PAIRimmune is more than a preclinical contract research organisation (CRO) for early proof-of-concept studies with adapted immune readouts.
In May 2017, Chinese animal vaccine company Jinyu Bio-technology unveiled plans to establish its first US-based vaccine research lab and office facility, located in Kansas.
Thank you for submitting the form. Your enquiry will be submitted to the company.
Thank you for subscribing to Pharmaceutical Technology